Elicio Therapeutics, Inc. ELTX
We are a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mutant Kirsten rat sarcoma viral oncogene homolog ("mKRAS") - positive pancreatic cancer, colorectal cancer ("CRC"), lung cancer and other mKRAS positive cancers. We intend to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Our proprietary Amphiphile ("AMP") technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Recent advances have identified T cell responses as a key component of effective cancer immunotherapy and we believe our AMP technology can generate robust T cell responses in patients that can potentially translate to meaningful clinical benefit.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $2.3M | $27.5M | $193.0K | — |
| Cost of revenue | — | — | — | $0 | $433.0K | $1.2M | — |
| Gross profit | — | — | — | $2.3M | $27.1M | -$997.0K | — |
| R&D | $24.9M | $33.7M | $23.8M | $18.1M | $48.7M | $39.0M | — |
| SG&A | $12.8M | $11.3M | $11.9M | $5.6M | $18.5M | $18.0M | — |
| Total operating expenses | $37.7M | $45.0M | $35.7M | $23.7M | $67.6M | $58.2M | — |
| Operating income | -$37.7M | -$45.0M | -$35.7M | -$23.7M | -$39.3M | -$55.3M | — |
| Interest expense | $1.1M | $455.0K | $1.1M | $3.6M | $1.8M | $8.8M | — |
| Pre-tax income | -$39.6M | -$51.9M | -$35.2M | -$38.8M | -$54.6M | -$80.1M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$39.6M | -$51.9M | -$35.2M | -$28.2M | -$54.6M | -$80.1M | — |
| EPS, basic | -2.58 | -4.25 | -6.96 | -89.27 | -1.93 | -5.43 | — |
| EPS, diluted | -2.58 | -4.25 | -6.96 | -89.27 | -1.93 | -5.43 | — |
| Shares, diluted (wtd. avg.) | $15.3M | $12.2M | $9.7M | $316.0K | $28.2M | $14.8M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $18.6M | $17.6M | $14.3M | $8.4M | $10.0M | $34.6M | $5.6M |
| Total current assets | $19.3M | $20.7M | $16.3M | $10.7M | $91.2M | $42.3M | — |
| Property, plant and equipment | $295.0K | $483.0K | $717.0K | $1.1M | $451.0K | $156.0K | — |
| Total assets | $25.9M | $28.2M | $27.1M | $22.7M | $96.5M | $47.3M | — |
| Accounts payable | $672.0K | $1.0M | $4.4M | $2.8M | $4.7M | $5.6M | — |
| Total current liabilities | $8.1M | $11.5M | $9.8M | $6.9M | $11.3M | $107.4M | — |
| Long-term debt | $9.4M | $20.0M | — | — | $0 | $635.0K | — |
| Total liabilities | $24.2M | $39.5M | $15.8M | $13.7M | $15.0M | $137.8M | — |
| Retained earnings | -$233.7M | -$194.1M | -$142.2M | -$107.0M | -$215.1M | -$160.6M | — |
| Total equity | $1.6M | -$11.3M | $11.4M | -$102.1M | -$74.5M | -$90.4M | -$18.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$37.0M | -$37.1M | -$32.7M | -$22.2M | -$52.6M | -$22.9M | — |
| Depreciation and amortisation | $204.0K | $321.0K | $382.0K | $390.0K | $91.0K | $98.0K | — |
| Stock-based compensation | $2.7M | $1.5M | $1.2M | $579.0K | $12.0M | $4.7M | — |
| Capital expenditure | $16.0K | $87.0K | $66.0K | $654.0K | $382.0K | $41.0K | — |
| Investing cash flow | -$16.0K | -$84.0K | -$32.0K | -$654.0K | -$382.0K | -$41.0K | — |
| Financing cash flow | $36.7M | $42.3M | $38.6M | $21.2M | $107.2M | $52.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001601485-26-000035.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |